Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease.
Josefin Sundh, Anders Magnuson, Marika Kvarnström et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, open-label, phase 4 randomized trial evaluated the effects of metoprolol in 1695 patients aged 40 and older with chronic obstructive pulmonary disease (COPD) and no cardiovascular disease. The study found that metoprolol did not significantly improve the time to the first occurrence of a COPD exacerbation, cardiovascular event, or death, with 27% of patients on metoprolol experiencing the primary endpoint compared to 30% on standard care (hazard ratio, 0.87).
Key findings
- 27% of patients on metoprolol experienced the primary endpoint compared to 30% on standard care.
- Hazard ratio for COPD exacerbations was 0.88 (95% CI, 0.72 to 1.06).
- Serious adverse events occurred in 9.4% of the metoprolol group versus 7.8% in the standard care group.
- Nonserious adverse events were reported in 34.6% of the metoprolol group compared to 29.2% in the standard care group.
Why it matters
The findings suggest that metoprolol may not provide significant benefits in managing COPD exacerbations or related events in patients without cardiovascular disease, which is important for treatment decision-making.